Display Settings:

Format

Send to:

Choose Destination

    Int J Obes (Lond). 2008 Oct;32(10):1537-44. Epub 2008 Aug 19.

    First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes.

    Venditti EM, Bray GA, Carrion-Petersen ML, Delahanty LM, Edelstein SL, Hamman RF, Hoskin MA, Knowler WC, Ma Y; Diabetes Prevention Program Research Group.

    Collaborators (393)
    Bray GA, Culbert IW, Champagne CM, Eberhardt B, Greenway F, Guillory FG, Herbert AA, Jeffirs ML, Kennedy BM, Lovejoy JC, Morris LH, Melancon LE, Ryan D, Sanford DA, Smith KG, Smith LL, St Amant JA, Tulley RT, Vicknair PC, Williamson D, Zachwieja JJ, Polonsky KS, Tobian J, Ehrmann D, Matulik MJ, Clark B, Czech K, DeSandre C, Hilbrich R, McNabb W, Semenske AR, Caro JF, Watson PG, Goldstein BJ, Smith KA, Mendoza J, Liberoni R, Pepe C, Spandorfer J, Donahue RP, Richard P RB, Prineas R, Rowe P, Calles J, Cassanova-Romero P, Florez HJ, Giannella A, Kirby L, Larreal C, McLymont V, Mendez J, Ojito J, Perry A, Saab P, Haffner SM, Montez MG, Lorenzo C, Martinez A, Hamman RF, Nash PV, Testaverde L, Anderson DR, Ballonoff LB, Bouffard A, Calonge BN, Delve L, Farago M, Hill JO, Hoyer SR, Jortberg BT, Lenz D, Miller M, Price DW, Regensteiner JG, Seagle H, Smith CM, Steinke SC, VanDorsten B, Horton ES, Lawton KE, Arky RA, Bryant M, Burke JP, Caballero E, Callaphan KM, Ganda OP, Franklin T, Jackson SD, Jacobsen AM, Kula LM, Kocal M, Malloy MA, Nicosia M, Oldmixon CF, Pan J, Quitingon M, Rubtchinsky S, Seely EW, Schweizer D, Simonson D, Smith F, Solomon CG, Warram J, Kahn SE, Montgomery BK, Fujimoto W, Knopp RH, Lipkin EW, Marr M, Trence D, Kitabchi AE, Murphy ME, Applegate WB, Bryer-Ash M, Frieson SL, Imseis R, Lambeth H, Lichtermann LC, Oktaei H, Rutledge LM, Sherman AR, Smith CM, Soberman JE, Williams-Cleaves B, Metzger BE, Johnson MK, Behrends C, Cook M, Fitzgibbon M, Giles MM, Heard D, Johnson CK, Larsen D, Lowe A, Lyman M, McPherson D, Molitch ME, Pitts T, Reinhart R, Roston S, Schinleber PA, Nathan DM, McKitrick C, Turgeon H, Abbott K, Anderson E, Bissett L, Cagliero E, Delahanty L, Goldman V, Poulos A, Olefsky JM, Carrion-Petersen ML, Barrett-Connor E, Edelman SV, Henry RR, Horne J, Janesch SS, Leos D, Mudaliar S, Polonsky W, Smith J, Vejvoda K, Pi-Sunyer FX, Lee JE, Allison DB, Aronoff NJ, Crandall JP, Foo ST, Pal C, Parkes K, Pena MB, Rooney ES, Van Wye GE, Viscovich KA, Marrero DG, Prince MJ, Kelly SM, Dotson YF, Fineberg ES, Guare JC, Hadden AM, Ignaut JM, Jackson ML, Kirkman MS, Mather KJ, Porter BD, Roach PJ, Rowland ND, Wheeler ML, Ratner RE, Youssef G, Shapiro S, Bavido-Arrage C, Boggs G, Bronsord M, Brown E, Cheatham WW, Cola S, Evans C, Gibbs P, Kellum T, Levatan C, Nair AK, Passaro M, Uwaifo G, Saad MF, Budget M, Jinagouda S, Akbar K, Conzues C, Magpuri P, Ngo K, Rassam A, Waters D, Xapthalamous K, Santiago JV, Dagogo-Jack S, White NH, Das S, Santiago A, Brown A, Fisher E, Hurt E, Jones T, Kerr M, Ryder L, Wernimont C, Saudek CD, Bradley V, Sullivan E, Whittington T, Abbas C, Brancati FL, Clark JM, Charleston JB, Freel J, Horak K, Jiggetts D, Johnson D, Joseph H, Loman K, Mosley H, Rubin RR, Samuels A, Stewart KJ, Williamson P, Schade DS, Adams KS, Johannes C, Atler LF, Boyle PJ, Burge MR, Canady JL, Chai L, Gonzales Y, Hernandez-McGinnis DA, Katz P, King C, Rassam A, Rubinchik S, Senter W, Waters D, Shamoon H, Brown JO, Adorno E, Cox L, Crandall J, Duffy H, Engel S, Friedler A, Howard-Century CJ, Kloiber S, Longchamp N, Martinez H, Pompi D, Scheindlin J, Violino E, Walker E, Wylie-Rosett J, Zimmerman E, Zonszein J, Orchard T, Wing RR, Koenning G, Kramer MK, Barr S, Boraz M, Clifford L, Culyba R, Frazier M, Gilligan R, Harrier S, Harris L, Jeffries S, Kriska A, Manjoo Q, Mullen M, Noel A, Otto A, Semler L, Smith CF, Smith M, Venditti E, Weinzierl V, Williams KV, Wilson T, Arakaki RF, Latimer RW, Baker-Ladao NK, Beddow R, Dias L, Inouye J, Mau MK, Mikami K, Mohideen P, Odom SK, Perry RU, Knowler WC, Cooeyate N, Hoskin MA, Percy CA, Acton KJ, Andre VL, Barber R, Begay S, Bennett PH, Benson MB, Bird EC, Broussard BA, Chavez M, Dacawyma T, Doughty MS, Duncan R, Edgerton C, Ghahate JM, Glass J, Glass M, Gohdes D, Grant W, Hanson RL, Horse E, Ingraham LE, Jackson M, Jay P, Kaskalla RS, Kessler D, Kobus KM, Krakoff J, Manus C, Michaels S, Morgan T, Nashboo Y, Nelson JA, Poirier S, Polczynski E, Reidy M, Roumain J, Rowse D, Sangster S, Sewenemewa J, Tonemah D, Wilson C, Yazzie M, Bain R, Fowler S, Brenneman T, Abebe S, Bamdad J, Callaghan J, Edelstein SL, Gao Y, Grimes KL, Grover N, Haffner L, Jones S, Jones TL, Katz R, Lachin JM, Mucik P, Orlosky R, Rochon J, Sapozhnikova A, Sherif H, Stimpson C, Temprosa M, Walker-Murray F, Marcovina S, Strylewicz G, Aldrich FA, Eastman R, Fradkin J, Garfield S.

    Psychiatric Institute and Clinic, Pittsburgh, PA, USA. dppmail@biostat.bsc,gwu.edu

    Erratum in:

    • Int J Obes (Lond). 2009 Jan;33(1):182.

    OBJECTIVE: Following unblinding of the Diabetes Prevention Program (DPP) results, a 16-session lifestyle intervention program was offered to all study participants, including those who had initially been randomized to lifestyle treatment. This study compares the effects of the lifestyle program between participants who had previous exposure and those who had not. DESIGN: A 16-session behavioral intervention was conducted in groups at each of the 27 DPP sites during a transitional (bridge) period from the DPP trial to the DPP Outcomes Study (DPPOS). Session participation for this 6-month behavioral weight loss program was confirmed by originally randomized treatment groups. SUBJECTS AND MEASUREMENTS: Independently assessed weight measurements were available within a 7-month period before and after the program for 2808 ethnically diverse participants. RESULTS: Participants from the lifestyle group in the DPP were the least likely to attend a repeat offering of a 16-session behavioral weight loss program conducted in groups. Weight loss during the transitional lifestyle program was strongly related to the duration of attendance in the three groups that were participating in the program for the first time (metformin, placebo and troglitazone), but not related to amount of earlier weight loss. CONCLUSION: Individuals who were naive to the behavioral program lost a greater amount of weight and this was strongly related to their degree of participation. A second exposure to a behavioral weight loss program resulted in unsatisfactory low attendance rates and weight loss.

    PMID: 18711387 [PubMed - indexed for MEDLINE]

    PMCID: 2574826

    Supplemental Content

    Click here to read Click here to read Click here to read Click here to read Click here to read

    Patient drug information

    • Metformin (Fortamet®, Glucophage®, Glucophage® XR, ...)

      Metformin is used alone or with other medications, including insulin, to treat type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood) ....